CompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...

We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...

Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...

At the State of Black Health second annual summit hosted by BlackDoctor.org in partnership with USA TODAY, corporate leaders ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) saw some unusual options trading activity on Thursday. Stock investors bought 16,698 call options on the stock. This represents an increase of ...

Galapagos NV’s split could unlock value despite short-term share decline. Learn why GLPG stock’s strategic focus offers ...

Gilead Sciences Inc. closed 1.35% below its 52-week high of $106.69, which the company achieved on February 14th.

Deutsche Bank upgraded Gilead (GILD) to Buy from Hold with a price target of $120, up from $80. The company’s core HIV treatment franchise ...